In silico prediction of ADME and pharmacokinetics: Report of an expert meeting organised by COST B15

European Journal of Pharmaceutical Sciences

Volumn 17, Issue 4-5, 2002, Pages 183-193

  Boobis, Alan ^a   Gundert Remy, Ursula ^b   Kremers, Pierre ^c   Macheras, Panos ^d   Pelkonen, Olavi ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Assessment of Chemicals   (Germany)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

ADME; In silico; Metabolism; Pharmacokinetics; Prediction

Indexed keywords

ABSORPTION; DATABASE SYSTEMS; DRUG PRODUCTS; METABOLISM; TOXICITY;

SILICO PREDICTIONS;

PHARMACOKINETICS;

CYTOCHROME P450; DRUG;

COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER PROGRAM; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; TECHNOLOGY; VALIDATION PROCESS; ADSORPTION; BIOAVAILABILITY; CHEMICAL MODEL; COMPUTER SIMULATION; DRUG EFFECT; METABOLISM; METHODOLOGY; PHARMACEUTICS; PREDICTION AND FORECASTING;

ADSORPTION; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; SOFTWARE; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036891062     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00185-9     Document Type: Conference Paper

References (46)

1. Aarons L., Balant L., Boobis A.R. Cost B15: modelling in drug development. Br. J. Clin. Pharmacol. 52:2001;118-119.
2. Agoran B., Woltosz W.S., Bolger M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50:2001;S41-S67.
3. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:1995;413-420.
4. Bergstrom C.A.S., Norinder U., Luthman K., Artursson P. Experimental and computational screening models for the prediction of aqueous drug solubility. Pharm. Res. 19:2002;182-188.
5. Bogdanffy M.S., Plowchalk D.R., Sarangapani R., Starr T.B., Andersen M.E. Mode-of-action-based dosimeters for interspecies extrapolation of vinyl acetate inhalation risk. Inhal. Toxicol. 13:2001;377-396.
6. Boxenbaum H. Absorption potential and its variants. Pharm. Res. 16:1999;1893.
7. Clewell H.J., Gentry P.R., Gearhart J.M., Allen B.C., Andersen M.E. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total Environ. 274:2001;37-66.
8. Darvas F., Markohazy S., Kormos P., Kulkami G., Kalasz H., Papp A. MetabolExpert: Its use in metabolism research and in combinatorial chemistry. Erhardt P.W., Drug Metabolism: Databases and High-throughput Screening Testing During Drug Design and Development. 1999;237-270.
9. Dressman J.B., Amidon G.L., Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74:1985;588-589.
10. Ekins S., Wrighton S.A. Application of in silico approaches to predicting drug-drug interactions. J. Pharmacol. Toxicol. Methods. 45:2001;65-69.
11. Ekins S., Waler C.L., Swaan P.W., Cruciani G., Wrighton S.A., Wikel J.H. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods. 44:2000;251-272.
12. Grass G.M. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Deliv. Rev. 23:1997;199-219.
13. Ho N.F., Higuchi W.I., Tun J. Theoretical model studies of drug absorption and transport in the GI tract (3). J. Pharm. Sci. 61:1972;192-197.
14. Hodgson J. ADMET - turning chemicals into drugs. Nat. Biotechnol. 19:2001;722-726.
15. Hogben C.A.M., Tocco D.J., Brodie B.B., Schanker L.S. On the mechanism of intestinal absorption of drugs. J. Pharmacol. Exp. Ther. 125:1959;275-282.
16. Jenner P., Testa B., Concepts in Drug Metabolism. 1981;Marcel Dekker, New York.
17. Jones J.P., Mysinger M., Korzekwa K.R. Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab. Dispos. 30:2002;7-12.
18. Jonsson F., Johanson G. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol. Appl. Pharmacol. 174:2001;99-112.
19. Kalampokis A., Argyrakis P., Macheras P. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. Pharm. Res. 16:1999;1764-1769.
20. Kalampokis A., Argyrakis P., Macheras P. Heterogeneous tube model for the study of small intestinal transit flow. Pharm. Res. 16:1999;87-91.
21. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today. 2:1997;436-444.
22. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors and inducers. Drug Metab. Rev. 34:2002;47-54.
23. Kumar G.N., Surapaneni S. Role of drug metabolism in drug discovery and development. Med. Res. Rev. 21:2001;397-411.
24. Lombardo F., Obach R.S., Shalaeva M.Y., Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 45:2002;2867-2876.
25. Macheras P., Symillides M. Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept. Biopharm. Drug Dispos. 10:1989;43-53.
26. Norris D.A., Leesman G.D., Sinko P.J., Grass G.M. Development of predictive pharmacokinetic simulation models for drug discovery. J. Controlled Release. 65:2000;55-62.
27. Oh D.M., Curl R.L., Amidon G.L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. 10:1993;264-270.
28. Oliver R.E., Jones A.F., Rowland M. A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J. Pharmacokinet. Biopharm. 28:2001;27-55.
29. Poulin P., Theil F.P. A priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89:2000;16-35.
30. Poulin P., Theil F.P. Prediction of pharamcokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91:2002;129-156.
31. Poulin P., Theil F.P. Prediction of pharamcokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91:2002;1358-1370.
32. Poulin P., Schoenlein K., Theil F.P. Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs. J. Pharm. Sci. 90:2001;436-447.
33. Prentis R.A., Lis Y., Walker S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:1988;387-396.
34. Sinko P.J., Leesman G.D., Amidon G.L. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8:1991;979-988.
35. Stenberg P., Norinder U., Luthman K., Artursson P. Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 44:2001;1927-1937.
36. Stoll B.R., Batycky R.P., Leipold H.R., Milstein S., Edwards D.A. A theory of molecular absorption from the small intestine. Chem. Eng. Sci. 55:2000;473-489.
37. Suzuki A., Higuchi W.I., Ho N.F. Theoretical model studies of drug absorption and transport in the gastrointestinal tract I. J. Pharm. Sci. 59:1970;644-651.
38. Suzuki A., Higuchi W.I., Ho N.F. Theoretical model studies of drug absorption and transport in the gastrointestinal tract II. J. Pharm. Sci. 59:1970;651-659.
39. ter Laak A.M., Vermeulen N.P.E. Molecular modeling approaches to predict drug metabolism and toxicity: a summary. Testa B., van de Waterbeemd H., Folkers G., Guy R., Pharmacokinetic Optimization in Drug Research - Biological, Physicochemical and Computational Strategies. 2001;551-588 Wiley-VCH, Helvetica Chimica Acta, Zürich.
40. Testa B. The Metabolism of Drugs and Other Xenobiotics-Biochemistry of Redox Reactions. 1995;Academic Press, London.
41. Testa B., Cruciani G. Structure-metabolism relations and the challenge of predicting biotransformation. Testa B., van de Waterbeemd H., Folkers G., Guy R., Pharmacokinetic Optimization in Drug Research - Biological, Physicochemical and Computational Strategies. 2001;65-84 Wiley-VCH, Helvetica Chimica Acta, Zürich.
42. Testa B., Jenner P. Drug Metabolism: Chemical and Biochemical Aspects. 1976;Marcel Dekker, New York.
43. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:2000;145-154.
44. Wessel K., Jurs P.C., Tolan J.W., Muscal S.M. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38:1998;726-735.
45. Yu L.X., Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186:1999;119-125.
46. Zhao Y.H., Le J., Abraham M.H., Hersey A., Eddershaw P.J., Luscombe C.N., Boutina D., Beck G., Sherborne B., Cooper I., Platts J.A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. 90:2001;749-784.